Biohaven registers Phase 2b/3 study of BHV-1300 in Graves' Disease
The study, led by Biohaven Therapeutics Ltd., plans to enroll an estimate of 356 participants to evaluate the safety and tolerability of BHV-1300 in adults with Graves' Disease. It plans to start in October 2026 and reach primary completion in December 2028.
Primary source
ClinicalTrials.gov registry record, October 28, 2026
An Open-Label Study to Determine if BHV-1300 is Safe in Adults With Graves' Disease
Read the source: An Open-Label Study to Determine if BHV-1300 is Safe in Adults With Graves' Disease clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation